广西医科大学学报2017，Vol.34Issue(3)：332-337,6.DOI:10.16190/j.cnki.45-1211/r.2017.03.003
人弥漫大B细胞淋巴瘤阿霉素耐药细胞株的建立及其生物学特性研究
Establishment of adriamycin-resistant human diffuse large B-cell lymphoma cell lines and study on its characteristics
摘要
Abstract
Objective:To establish adriamycin-resistant human diffuse large B-cell lymphoma (DLBCL) cell lines.Methods:Human DLBCL cells (Pfeiffer) were exposed in stepwise escalating concentration of adriamycin until the resistant cell line (Pfeiffer/ADM) was developed.The morphology and cell doubling time of Pfeiffer and Pfeiffer/ADM cells were compared under the microscope.The drug resistance fold,stability and rituximab (RTX)-mediated complement-dependent cytotoxicity were detected by CCK-8 assay.The multidrug resistance 1 (MDR1) mRNA expression was detected by quantitative real-time PCR (qRTPCR).Results:Pfeiffer/ADM cell line was established after 7 months of induction.In a medium contained adriamycin,Pfeiffer/ADM grew well,but most of Pfeiffer cells were dead.The doubling time of Pfeiffer and Pfeiffer/ADM cells were (32.28±1.18) h and (31.41±2.03) h,respectively (P ＞0.05).CCK-8 assay showed that the indexes of drug resistant to adriamycin,etoposide and vincristine in Pfeiffer/ADM were 12.87,13.18 and 16.85,respectively.Pfeiffer/ADM remained drugs resistant in drug-free medium at least 1 month or after the recovery from the frozen.There was no significant difference between Pfeiffer and Pfeiffer/ADM in RTX-mediated complementdependent cytotoxicity (P ＞0.05).Pfeiffer/ADM was significantly higher than Pfeiffer in MDR1 mRNA expression (P ＜0.05).Conclusion:A DLBCL multi-drugs resistant cell line was established successfully,which was not cross-resistance to RTX.It could be an ideal model to study mechanisms of acquired drug resistance and reverse drug resistance.关键词
多药耐药/阿霉素/弥漫性大B细胞淋巴瘤/MDR1/利妥昔单抗Key words
multiple drug resistance/adriamycin/diffuse large B-cell lymphoma/MDR1/Rituximab分类
医药卫生引用本文复制引用
黄云,孙洁,柯晴,梁碧琦,谭晓虹,岑洪..人弥漫大B细胞淋巴瘤阿霉素耐药细胞株的建立及其生物学特性研究[J].广西医科大学学报,2017,34(3):332-337,6.基金项目
国家自然科学基金资助项目(No.81160298) （No.81160298）
广西医疗卫生适宜技术研究与开发项目(No.S201301-02) （No.S201301-02）
